预约演示
更新于：2025-04-19
DB-105
更新于：2025-04-19
概要
基本信息
原研机构 |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)临床2期 |
特殊审评- |
登录后查看时间轴
关联
15
项与 DB-105 相关的临床试验NCT03440021
The Effects of Single-dose Administration of a Novel Selective alpha2c Antagonist on Emotional and Cognitive Processing in Healthy Volunteers: an fMRI Investigation
EUCTR2014-000217-30-BG
EFFICACY OF ORM-12741 ON AGITATION/AGGRESSION SYMPTOMS IN PATIENTSWITH ALZHEIMER’S DISEASE: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED,PARALLEL GROUP, MULTICENTRE STUDY OF 12 WEEKS - NEBULA
NCT02471196
Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Patients With Alzheimer's Disease: A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre Study of 12 Weeks
100 项与 DB-105 相关的临床结果
登录后查看更多信息
100 项与 DB-105 相关的转化医学
登录后查看更多信息
100 项与 DB-105 相关的专利（医药）
登录后查看更多信息
6
项与 DB-105 相关的文献（医药）2020-12-01EJNMMI research3区 · 医学
Application of the PET ligand [11C]ORM-13070 to examine receptor occupancy by the α2C-adrenoceptor antagonist ORM-12741: translational validation of target engagement in rat and human brain
3区 · 医学
ArticleOA
作者: Solin, Olof ; Rouru, Juha ; Kuokkanen, Katja ; Rinne, Juha O ; Scheinin, Mika ; Virta, Jere ; Shahid, Mohammed ; Arponen, Eveliina ; Marjamäki, Päivi ; Sallinen, Jukka
Abstract:
Background:
Availability of the α2C-adrenoceptor (α2C-AR) positron emission tomography (PET) tracer, [11C]ORM-13070, and the α2C-AR antagonist ORM-12741 allows probing of the roles of this G-protein coupled receptor subtype in brain function, both in healthy humans and in patients with various brain disorders. This translational study employed [11C]ORM-13070 autoradiography and PET to determine α2C-AR occupancy by ORM-12741 in rat and human brain, respectively.
Results:
ORM-12741 has high affinity (Ki: 0.08 nM) and potent antagonist activity (Kb: 0.04 nM) as well as selectivity (Ki estimates for the human α2A-AR and α2B-AR were 8.3 nM and 0.8 nM, respectively) for the human α2C-AR subtype. [11C]ORM-13070 had highest uptake in the basal ganglia of rat and human brain. Pretreatment with ORM-12741 inhibited [11C]ORM-13070 binding in rat striatum in a time- and dose-dependent manner at 10 and 50 µg/kg (s.c.) with an EC50 estimate of 1.42 ng/mL in rat plasma, corresponding to protein-free drug concentration of 0.23 nM. In the living human brain, time- and dose-related α2C-AR occupancy was detected with EC50 estimates of 24 ng/mL and 31 ng/mL for the caudate nucleus and putamen, respectively, corresponding to protein-free concentrations in plasma of 0.07 nM and 0.1 nM. Modelling-based maximum α2C-AR occupancy estimates were 63% and 52% in the caudate nucleus and the putamen, respectively.
Conclusions:
ORM-12741 is a selective α2C-AR antagonist which penetrates the rat and human brain to occupy α2C-ARs in a manner consistent with its receptor pharmacology.Trialregistrationnumberanddateofregistration: ClinicalTrial.cov NCT00829907. Registered 11 December 2008. https://clinicaltrials.gov/.
2017-10-01Epilepsy research3区 · 医学
Disease-modifying effect of atipamezole in a model of post-traumatic epilepsy
3区 · 医学
Article
作者: Andrade, Pedro ; Nissinen, Jari ; Malm, Tarja ; Natunen, Teemu ; Hiltunen, Mikko ; Soares, Joana I ; Kanninen, Katja ; Ndode-Ekane, Xavier Ekolle ; Shatillo, Olena ; Sallinen, Jukka ; Pitkänen, Asla
Treatment of TBI remains a major unmet medical need, with 2.5 million new cases of traumatic brain injury (TBI) each year in Europe and 1.5 million in the USA. This single-center proof-of-concept preclinical study tested the hypothesis that pharmacologic neurostimulation with proconvulsants, either atipamezole, a selective α2-adrenoceptor antagonist, or the cannabinoid receptor 1 antagonist SR141716A, as monotherapy would improve functional recovery after TBI. A total of 404 adult Sprague-Dawley male rats were randomized into two groups: sham-injured or lateral fluid-percussion-induced TBI. The rats were treated with atipamezole (started at 30min or 7 d after TBI) or SR141716A (2min or 30min post-TBI) for up to 9 wk. Total follow-up time was 14 wk after treatment initiation. Outcome measures included motor (composite neuroscore, beam-walking) and cognitive performance (Morris water-maze), seizure susceptibility, spontaneous seizures, and cortical and hippocampal pathology. All injured rats exhibited similar impairment in the neuroscore and beam-walking tests at 2 d post-TBI. Atipamezole treatment initiated at either 30min or 7 d post-TBI and continued for 9 wk via subcutaneous osmotic minipumps improved performance in both the neuroscore and beam-walking tests, but not in the Morris water-maze spatial learning and memory test. Atipamezole treatment initiated at 7 d post-TBI also reduced seizure susceptibility in the pentylenetetrazol test 14 wk after treatment initiation, although it did not prevent the development of epilepsy. SR141716A administered as a single dose at 2min post-TBI or initiated at 30min post-TBI and continued for 9 wk had no recovery-enhancing or antiepileptogenic effects. Mechanistic studies to assess the α2-adrenoceptor subtype specificity of the disease-modifying effects of atipametzole revealed that genetic ablation of α2A-noradrenergic receptor function in Adra2A mice carrying an N79P point mutation had antiepileptogenic effects after TBI. On the other hand, blockade of α2C-adrenoceptors using the receptor subtype-specific antagonist ORM-12741 had no favorable effects on the post-TBI outcome. Finally, to assess whether regulation of the post-injury inflammatory response by atipametzole in glial cells contributed to a favorable outcome, we investigated the effect of atipamezole on spontaneous and/or lipopolysaccharide-stimulated astroglial or microglial cytokine release in vitro. We observed no effect. Our data demonstrate that a 9-wk administration of α2A-noradrenergic antagonist, atipamezole, is recovery-enhancing after TBI.
2017-04-13Expert opinion on pharmacotherapy3区 · 医学
An update on the advancements in the treatment of agitation in Alzheimer’s disease
3区 · 医学
Review
作者: Porsteinsson, Anton P. ; Antonsdottir, Inga M.
INTRODUCTION:
Neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) are associated with significant negative outcomes for patients and their caregivers. Agitation, one of the most distressing NPS, lacks safe and effective long term interventions. Nonpharmacological interventions are suggested as first-line treatment, but aren't effective for every patient, resulting in pharmacological interventions for some patients, consisting of off-label use of antipsychotics, sedative/hypnotics, anxiolytics, acetylcholinesterase inhibitors, memantine, and antidepressants; where efficacy doesn't necessarily outweigh associated risks. Areas covered: Gains in understanding neurobiological mechanisms underlying agitation have fueled several recent clinical trials. This article updates our review published in 2014. Comprehensive literature search for published articles from January 2014 to December 2016 evaluating pharmacologic interventions for agitation in AD was done. A review of several clinical trials was completed: dextromethorphan/quinidine, scyllo-inositol, brexpiprazole, prazosin, cannabinoids, citalopram, escitalopram, pimavanserin, ITI-007, ORM-12741 show promise in treating agitation. Expert opinion: Neurobiological findings, innovative trials designs, statistical approaches, and preliminary paths for regulatory agency acceptance have re-ignited the area of pharmacological treatment of NPS. Though further research is needed to fully determine the safety, tolerability and efficacy of these treatments, the mission to find effective treatments for neuropsychiatric symptoms such as agitation in patients with dementia is well underway.
7
项与 DB-105 相关的新闻（医药）2023-11-01
·药时代
临床3期上市批准基因疗法引进/卖出申请上市
2023-09-21
·药时代
临床3期上市批准
2023-06-11
·药时代
临床3期加速审批上市批准抗体药物偶联物
100 项与 DB-105 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 攻击 | 临床2期 | 芬兰 | 2015-08-14 | |
| 攻击 | 临床2期 | 芬兰 | 2015-08-14 | |
| 躁动 | 临床2期 | 芬兰 | 2015-08-14 | |
| 躁动 | 临床2期 | 芬兰 | 2015-08-14 | |
| 阿尔茨海默症 | 临床2期 | 芬兰 | 2011-04-01 | |
| 系统性硬皮病 | 临床2期 | 英国 | 2011-03-01 | |
| 血管痉挛 | 临床2期 | 英国 | 2011-03-01 | |
| 雷诺病 | 临床2期 | 英国 | 2011-03-01 | |
| 精神分裂症 | 临床2期 | 欧洲 | - | |
| 精神分裂症 | 临床2期 | - | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 100 | (Low Dose of ORM-12741) | 憲衊願淵鹽壓選簾廠淵 = 衊衊積廠齋築鑰壓選鏇 廠鬱膚夢築餘簾鏇鹽簾 (願獵遞壓淵壓醖衊窪繭, 積鑰築獵餘選鏇鏇簾遞 ~ 繭範糧顧築糧醖糧壓鬱) 更多 | - | 2021-04-28 | ||
(High Dose of ORM-12741) | 憲衊願淵鹽壓選簾廠淵 = 衊繭觸範製選窪鬱簾壓 廠鬱膚夢築餘簾鏇鹽簾 (願獵遞壓淵壓醖衊窪繭, 獵簾願鹹衊構壓獵壓網 ~ 鹽糧艱積憲壓製鑰觸醖) 更多 | ||||||
临床2期 | 100 | 獵繭鏇壓壓網膚範鏇齋(鹽醖齋鹽淵積窪餘廠選): P-Value = 0.030 更多 | 积极 | 2016-12-08 | |||
Placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和Eureka LS聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用